Expression Vector Element Combinations for Antibody Production

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current expression vector designs differ in performance between transient and stable transfections, requiring optimized vector organizations for each, and existing methods are inefficient in identifying high-producing cell clones for recombinant antibody production.

Innovation Solution

The use of expression vectors with specific promoter and polyA signal combinations, such as the human cytomegalovirus (hCMV) promoter with bovine growth hormone (bGH) polyA signal and human gastrin terminator, and the human elongation factor 1 alpha (hEF1α) promoter with bGH polyA signal, in unidirectional or bidirectional arrangements, to enhance antibody production and stability in mammalian cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If conventional expression vector designs are used, then the basic function of protein expression is achieved, but the number of antibody-producing cells is limited and identification of high-producing clones is time-consuming

Engineering Contradiction:
Improvenumber of antibody-producing cellsVSAvoidtime required to identify high-producing clones
Core Design Contradiction:
ProductivityVSLoss of time

Solution Approach 1:

The patent optimizes vector elements (promoter strength, polyA signal sequence, transcription terminator) to change expression parameters, resulting in a 10-100 fold increase in antibody-producing cells and reduced time to identify high-producing clones

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent incorporates pre-optimized expression elements and selection markers into the vector design before transfection, enabling rapid identification of high-producing clones without requiring extensive screening time

Inventive Principle:
Principle #10Preliminary action

2Productivity

If expression vectors are optimized for transient transfection, then high expression levels are achieved in the short term, but stability of expression is reduced

Engineering Contradiction:
Improveexpression levelVSAvoidexpression stability
Core Design Contradiction:
ProductivityVSStability of the object's composition

Solution Approach 1:

The patent separates vector elements into distinct functional modules (promoter, polyA signal, terminator) that can be independently optimized for different transfection types, allowing tailored vector designs for transient versus stable expression

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The patent modifies specific vector parameters (e.g., promoter strength, polyA signal sequence) to achieve different expression profiles - stronger promoters and optimized polyA signals for transient expression, while stable integration elements for long-term stable transfection

Inventive Principle:
Principle #35Parameter changes

3Stability of the object's composition

If expression vectors are optimized for stable transfection, then long-term expression stability is achieved, but the number of antibody-producing cells is reduced

Engineering Contradiction:
Improveexpression stabilityVSAvoidnumber of antibody-producing cells
Core Design Contradiction:
Stability of the object's compositionVSProductivity

Solution Approach 1:

The patent divides vector elements into separate functional components that can be independently optimized, allowing the selection of optimal combinations for stable transfection that maximize both stability and productivity

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The patent creates composite vector designs combining multiple optimized elements (e.g., hCMV promoter with bGH polyA signal and hGT terminator) to achieve synergistic effects that simultaneously improve stability and increase the number of antibody-producing cells

Inventive Principle:
Principle #40Composite materials

Data Source

PatentEP2794651B1Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
Publication Date: 2022.09.21 F HOFFMANN LA ROCHE & CO AG
  • EP2794651B1 patent drawingFigure 1
  • EP2794651B1 patent drawingFigure 2
  • EP2794651B1 patent drawingFigure 3

AI summary

Herein is reported that for transient transfections the use of the human elongation factor 1 alpha promoter (with Intron A) provides for an enhanced productivity (in LC-HC-SM organization), the use of the bovine growth hormone polyA signal sequence provides for an enhanced productivity compared to use of the SV40 polyA signal sequence, the addition of the HGT to the bGH PolyA signal sequence results in an increased productivity in vectors containing the hCMV promoter and the vector organization LC(3` -5 ')-HC-SM results in improved expression. For stable pools it is reported that pools generated with vectors containing the hEF1alpha promoter show an enhanced productivity in batch analysis, clones generated with vectors containing the hEF1alpha promoter show a reduced number of low producing clones, and clones generated with vectors containing the hEF1alpha promoter show a higher stability of IgG expression. For single clones it is reported that the vector organization with downstream position of selection marker (LC-HC-SM) has a positive effect on productivity of single clones and that clones generated with vectors containing the bGH polyA signal sequence and the hGT have higher productivities.